From WikiProjectMed
Jump to navigation Jump to search

Trade namesOncaspar
  • Pegylated E. coli L-asparagine amidohydrolase
Clinical data
Main usesAcute lymphoblastic leukemia (ALL)[1]
Side effectsAllergic reactions, blood clotting problems, high blood sugar, liver problems, pancreas inflammation, blood clots in the brain[2]
  • US: C (Risk not ruled out)
Routes of
Intramuscular injection (IM), intravenous (IV)
Defined daily doseNot established[3]
External links
US NLMPegaspargase
License data
Legal status
Chemical and physical data
Molar mass31732.06 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pegaspargase, sold under the trade name Oncaspar, is a medication used in the treatment of acute lymphoblastic leukemia (ALL).[1] Often it is used together with anthracycline, vincristine, and prednisone.[2] It is used by injection.[2]

Common side effects include allergic reactions, blood clotting problems, high blood sugar, liver problems, pancreas inflammation, and blood clots in the brain.[2] Its use during pregnancy may harm the baby.[4] It is a modified version of the enzyme asparaginase which has undergone PEGylation.[5][2] It works by breaking down asparagine, decreasing its availability to make protein.[2]

Pegaspargase was approved for medical use in the United States in 1994.[2] It is on the World Health Organization's List of Essential Medicines.[6] It is made by Sigma-Tau.[2] In the United States it costs about $US17,800 per 3,750 units vial.[7]


The defined daily dose is not established.[3]


  1. 1.0 1.1 Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 "Pegaspargase Monograph for Professionals". Retrieved 11 October 2019.
  3. 3.0 3.1 "WHOCC - ATC/DDD Index". Retrieved 9 September 2020.
  4. "Pegaspargase (Oncaspar) Use During Pregnancy". Retrieved 11 October 2019.
  5. "UNM Cancer Center". Archived from the original on 3 September 2006. Retrieved 28 August 2007.
  6. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  7. "Oncaspar Prices, Coupons & Patient Assistance Programs". Retrieved 11 October 2019.

External links

External sites: